ST. LOUIS, Sept. 20 /PRNewswire/ — Stereotaxis, Inc. (Nasdaq:
STXS) today announced that the U.S. Patent and Trademark Office
granted the Company its 100th patent, a major intellectual property
milestone. The 100th patent, U.S. patent No. 7,772,950, covers the
“Method and Apparatus for Dynamic Magnetic Field Control Using
Multiple Magnets.” The 100th patent reflects Stereotaxis’
ongoing commitment to innovate and protect its leading position in
robotic solutions for interventional medicine.
“Our 100th patent represents a significant milestone in
Stereotaxis’ drive to protect shareholder value and deliver
innovative technologies that improve treatment options for patients
with cardiovascular disease,” said Michael P. Kaminski, President
and Chief Executive Officer. “Our strong intellectual property
position enables the delivery of measurable clinical benefits
across the broadest range of cardiovascular, neurovascular,
peripheral vascular and other interventional applications,
including treatment of ventricular tachycardia with high levels of
acute success.”
For more than 15 years, Stereotaxis has built a robust
intellectual property portfolio, which includes these 100 issued
patents and over 100 additional patent applications in process for
approval. Stereotaxis’ extensive U.S. patent portfolio is
supplemented by more than 30 non-U.S. patents and patent
applications. The Company anticipates doubling the number of
non-U.S. patents in the next few months as patents issue on its
Niobe® Magnetic Navigation System. The patents issued to date
include remote/robotic assisted cardiology procedures, diagnostic
integration, therapeutic devices, software automation, and
information technology for patient/case management.
For the past two years, Stereotaxis ranked in the top 10 of IEEE
Spectrum’s Patent Power Scorecard, a rating of the world’s
‘/>”/>
